Evidence map›Paper›PMID 27935810›Full record

ArticleEvidence-based mental health2016

Designing and analysing clinical trials in mental health: an evidence synthesis approach.

Simon Wandel, Satrajit Roychoudhury

Abstract read
In one paragraph

Article in Evidence-based mental health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Valproate for acute mania.The Cochrane database of systematic reviews · 2019
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Simon WandelNovartis Pharma AG, Basel, Switzerland.
Satrajit RoychoudhuryNovartis Pharmaceuticals, East Hanover, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWhen planning a clinical study, evidence on the treatment effect is often available from previous studies. However, this evidence is mostly ignored for the analysis of the new study. This is unfortunate, since using it could lead to a smaller study without compromising power. We describe a design that addresses this issue.

methodsWe use a Bayesian meta-analytic model to incorporate the available evidence in the analysis of the new study. The shrinkage estimate for the new study integrates the evidence from the other studies. At the planning phase of the study, it allows a statistically justified reduction of the sample size.

resultsThe design is illustrated using data from an Food and Drug Administration (FDA) review of lurasidone for the treatment of schizophrenia. Three studies inform the meta-analysis before the new study is conducted. Results from an additional phase III study, which were not available at the time of the FDA review, are then used for the actual analysis.

conclusionsIn the presence of reliable and relevant evidence, the design offers a way to conduct a smaller study without compromising power. It therefore fills a gap between the assessment of evidence and its actual use in the design and analysis of studies.

Indexed as

Meta-Analysis as TopicAntipsychotic AgentsBayes TheoremClinical Trials as TopicHumansLurasidone HydrochlorideMental HealthResearch DesignSample SizeSchizophreniaAntipsychotic AgentsLurasidone HydrochlorideMENTAL HEALTHSTATISTICS & RESEARCH METHODS

Identifiers

PMID27935810
PMCPMC10699521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.